NCT05534646 2026-02-02
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT02664961 2019-07-23
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Tracon Pharmaceuticals Inc.
Phase 2 Terminated
NCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT02396511 2019-06-11
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01381861 2019-03-05
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01727089 2018-08-28
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01375569 2017-07-28
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01328574 2017-01-13
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed